DEB-BACE for primary lung cancer: a safety and effectiveness study
Part of Cancer, Lungs & breathing clinical trials.
This study looks back at medical records of people with primary lung cancer who have already received a treatment called DEB-BACE (a type of chemo delivered directly to the lung tumor). The goal is to understand how well it works and how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with primary lung cancer (not cancer that started elsewhere)
- You are 18 years or older
- You have already received at least one DEB-BACE treatment (a procedure that delivers chemotherapy directly to the tumor)
- You are able to take care of yourself and do most daily activities (ECOG score 0 to 2)
- You do not have brain metastases that are out of control, serious bleeding problems, or uncontrolled heart disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to treat advanced NSCLC by combining two non-surgical procedures: bronchial artery infusion (BAI) and drug-eluting bead bronchial artery chemoembolization (DEB-BACE). It may be an option if you have stage III or IV lung cancer and standard treatments have failed or are not possible.
This trial is testing a new use of a procedure called BAI-BACE (injecting drugs or blocking blood flow through the bronchial artery) for people with advanced lung squamous cell carcinoma that hasn't responded to prior treatments. The goal is to see if this treatment can help control the cancer when it's still only in the chest.
This trial tests a combination of a new drug (D-BACE), chemotherapy, and carlizumab for people with a certain type and stage of lung cancer that can be removed with surgery. It aims to see if this combination helps shrink tumors and improves outcomes.
This trial tests a treatment called bronchial artery chemoembolization (BACE) combined with drug therapy for advanced non-small cell lung cancer. BACE delivers chemotherapy directly to the tumor through the blood vessel that feeds it, which may help control the cancer when standard treatments have stopped working.
This trial tests a second-line treatment called DEB-TACE (tiny beads filled with chemo placed directly into the tumor's blood supply) for people with large, hard-to-treat lymphoma tumors that have come back or not responded to other therapies. If you have at least one big tumor with good blood supply and have tolerated doxorubicin chemo before, this might be an option.
This trial studies two treatment schedules for unresectable, stage C liver cancer: one using Deb-TACE alone and one using Deb-TACE followed by HAIC. The goal is to see which plan works better for shrinking tumors and improving outcomes.
Hear when a new Lung Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.